Trial Profile
A Phase 1/2a Dose Escalation Study of PVX-410, a Multi-Peptide Cancer Vaccine, in Patients With Smoldering Multiple Myeloma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs PVX 410 (Primary) ; Lenalidomide; Poly ICLC
- Indications Smoldering multiple myeloma
- Focus Adverse reactions
- Sponsors OncoPep
- 06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
- 28 Nov 2016 Results published in an OncoPep media release.
- 28 Nov 2016 According to an OncoPep media release, data from the study will be presented at the 58th Annual Meeting of the American Society of Hematology (ASH).